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Abstract
In the present work, we report a facile and rapid green strategy to fabricate functionalized reduced nano-graphene
oxide (nrGO) as a cooperative nanotemplate for both photothermal therapy and drug loading. Graphite oxide was
firstly oxidated by nitronium ions (NO2
+) solution at the aid of microwave heating to obtain nano-GO (nGO) with
about 50 nm of diameter, and the nGO was then reduced in pure glucose at 135 °C for 30 min to obtain nrGO
with about 40 nm of diameter. The nrGO exhibits excellent biocompatibility including stable dispersibility in cell
culture medium and rapid cellular uptake as well as non-cytotoxicity up to 100 μg/mL. Absorption of the nrGO at
808 nm wavelength increased more than 10-folds compared with nGO. Moreover, the nrGO has the ability to load
about 317 % (w/w) of doxorubicin (DOX), and the loaded DOX could be effectively released by acid condition and/
or glutathione (GSH) and/or heating. Finally, a greater cancer cell death efficacy was observed in nrGO/DOX-treated
cells with GSH and heating stimulation respectively or their combination. Collectively, the nrGO developed here is
an outstanding cooperative nano-platform for high-efficiency photothermal therapy and controllable drug delivery.
Keywords: Nitronium oxidation, Functionalized graphene oxide, Glucose reduction, Biocompatibility, Photothermal
effect, Drug loading
Background
Graphene oxide (GO) has been widely used as an alter-
native and promising photo-absorbing agent for photo-
thermal therapy (PTT) due to its high photothermal
responsiveness, low toxicity, and low cost [1–3]. On the
basis of ultrahigh surface area and polyaromatic struc-
tures, GO is also available for efficiently loading aro-
matic hydrophobic drugs via hydrophobic interaction
and π-π stacking [4–6]. Reduced GO (rGO), owing to
the considerably enhanced optical absorbance and the
greatly restored conjugated structures, is more efficient
in PTT for large tumors or tumors deeply located inside
the body at relatively low power of near-infrared (NIR)
laser irradiation and also exhibits preferable drug carry-
ing capacity [7–10].
Due to the mild reduction ability, easy accessibility,
abundant oxidative groups composition, and nontoxic
merit, glucose is considered as an excellent green candi-
date for the reduction of GO [11–14]. Zhu and co-
workers for the first time used glucose as reductant to
reduce GO, and the reaction was carried out at 95 °C for
60 min in the presence of reducing sugar and ammonia
solution [11]. The ammonia solution was used as cata-
lyst to accelerate the reduction reaction synergistically
and benefit the deoxygenation of GO, and it was illus-
trated that such reducing capability was closely related
to the ability of the saccharides to form open-chain
structures [15]. Iron (Fe) was also used as catalyst to
accelerate the electron transfer between GO and glucose
[14]. In addition, Yuan and co-workers reduced GO in
glucose and ammonia solution under 95 °C for 2 h to
obtain rGO with increased specific surface area and enor-
mous micro- and meso-pore [12], and Shen and co-works
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glucose and ammonia in an autoclave under 160 °C for
4 h to obtain rGO with 4.59 of C/O ratio [13]. However,
these synthetic materials become sediments after centrifu-
gation, thus they are too heavy and unsuitable for loading
abundant drugs. Furthermore, both catalyst and bacteria
must be removed before cell application.
In this work, we developed a novel green route to re-
duce nano-GO (nGO) by adopting pure glucose as a
reductant to obtain reduced nano-graphene oxide
(nrGO). Prior to the reduction, nGO was prepared by a
simple microwave-enabled nitronium oxidation on
graphite oxide. The resulting nrGO has three marked ad-
vantages: (1) excellent biocompatibility: very stable for at
least 1 month in both water and cell culture medium
(DMEM); (2) effective photothermal effects: ~10.2-fold
increment in NIR absorption at 808 nm compared with
the unreduced nGO; and (3) high drug loading
capability: about 317 % (w/w) of loading capacity for
doxorubicin (DOX). In addition, loaded DOX can be
effectively released by acid condition and/or glutathione
(GSH) and/or heating. These characteristics make the
nrGO developed here a very excellent cooperative




Graphite oxide was prepared by a modified Hummer’s
method utilizing expandable graphite flake (XF NANO
Co., Ltd. China). For reoxidation, 12 mg of graphite
oxide was mixed with nitronium ion solution in a micro-
wave reaction kettle (Xi’an Often Instrument Equipment
Co. Ltd.) for 20 s, and then the entire mixture was
placed into a microwave reactor chamber (Midea,
MM823LA6-NS) to be heated for 3.75 min at the power
of 160 W. After the reactant was cooled by ice bath, the
reaction was quenched with 100 mL of deionized water,
neutralized by NaOH and Na2CO3, and ultrafiltered re-
peatedly through a 30-kDa filter (Millipore) to remove
the inorganic salt. At last, the graphite oxide of reoxida-
tion was sonicated (Xin Zhi, JY92-2D) at 612 W for 1 h
in an ice bath to obtain nGO. nGO-0, as a control, was
fabricated by sonication (Xin Zhi, JY92-2D) of graphite
oxide flake at 612 W for 1 h in an ice bath as described
previously [9].
Synthesis of nrGO
After 110 mg glucose was added to 5 mL nGO suspen-
sion (about 1 mg/mL) and sonicated for 30 min, the
mixture was transferred to autoclave and react at 135 °C
for 30 min to achieve sterile nrGO. The resulting nrGO
was stored at 4 °C for further use. nrGO-0 was prepared
by reducing nGO-0 similarly to the synthesis of nrGO.
Characterization of nrGO
The sheets of nGO-0, nGO, nrGO-0, and nrGO were
imaged with atomic force microscopy (AFM, Agilent
Technologies 5500, USA) on a mica substrate. UV-Vis
spectra were performed using a UV-Vis spectrometer
(Lambda 35, Perkin-Elmer, Waltham, MA, USA) with a
1-cm quartz cuvette. Absorption spectra were measured
by an auto microplate reader (Infinite M200, Tecan,
Austria). Fourier transform infrared (FTIR) spectra were
recorded on a FTIR spectrometer (Bruker Tensor 27,
Karlsruhe, Germany). To prepare nrGO samples without
non-covalently bound glucose for FTIR spectrometer
assay, NaCl was added to nrGO solutions to precipitate
nrGO irreversibly, and then the precipitation was centri-
fuged and rinsed ten times. Raman spectra were taken
with a Renishaw (New Mills, UK) inVia micro-Raman
spectroscopy system equipped with a 514.5-nm Ar+
laser. Luminescence Spectrometer (LS 55, PerkinElmer,
USA) was used to measure fluorescence emission of DOX
with 488 nm excitation. The images of all samples were
recorded using a digital camera (Nikon, Tokyo, Japan)
with 1280 × 1280 pixels resolution. The measurements of
size distribution, Zeta potential, and polydispersity index
(Pdi) of GO materials were conducted with the Zetasizer
(Malvern Instruments Ltd., UK), in which mean size = size
class (nm) × number distribution date (%).
Photothermal Irradiation
Eight-hundred-eight-nanometer laser with the power
density of 3 W/cm2 was used for NIR irradiation. Solu-
tions in Eppendorf tubes were continuously irradiated by
808 nm NIR laser for 8 min, and temperature was mea-
sured by a thermocouple thermometer (Fluke 51II, USA)
every other 1 min. All the experiments were conducted
at room temperature. All experiments were performed
in triplicate.
Loading and Release of DOX
To remove hydrogen chloride from doxorubicin hydro-
chloride salt (DOX · HCl), 1.3 equivalent of triethylamine
was added in DOX · HCl (16 mg) to DMSO (200 μL).
After being stirred for 12 h, the solution was filtrated to
remove the insoluble triethylamine hydrochloride and
the resulting DOX solution (80 mg/mL) was stored at
4 °C. The whole procedures were implemented in the
dark [16, 17].
Loading of DOX on nrGO was carried out by adding
DOX dissolved in DMSO (13.33 mg/ml) to nrGO aque-
ous suspension (0.1667 mg/ml) with shaking for 12 h.
The final volume ratio of DMSO to H2O was 0.5:10.
The product was repeatedly filtered through 30 kDa
filters (Millipore), soaked in distilled water to remove
free DOX and DMSO, and centrifuged at 6000 rpm to re-
move undissolved drug. DOX was loaded on nrGO-0 in
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the same way. The loading capacity of DOX on nrGO
was estimated by the auto microplate reader from the
absorbance at 488 nm, deducting the absorbance of
nrGO.
The amount of DOX released from nrGO/DOX under
different kinds of condition was estimated by measuring
the fluorescence at 604 with 488 nm laser excitation.
The solution with DOX-loaded nrGO (0.01 mg/mL)
was incubated at different conditions as diverse as a
range of GSH concentrations (0, 0.01, 0.05, 0.2, 0.5, 1,
and 5 mM), acidic condition (pH 5), or 50 °C water
bath for predetermined times to accelerate the embed-
ded drugs release. The amount of DOX release was
evaluated by measuring the DOX fluorescence via the
auto microplate reader.
Cell Culture
HepG2, Huh7, and A549 cell lines obtained from the
Department of Medicine, Jinan University (Guangzhou,
China) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco, Grand Island, USA) supple-
mented with 10 % fetal calf serum (FCS) in 5 % CO2,
95 % air at 37 °C in a humidified incubator.
Cell Uptake Assay
After A549 cells (1 × 105 cells) cultured in 6-well plates
with 1.5 mL DMEM for 24 h were incubated with
nrGO/DOX (5 μg/ml of DOX equivalent) in DMEM
(10 % fetal calf serum) for 1, 2, 6, and 12 h, respectively,
the cells were rinsed by phosphate-buffered saline (PBS)
five times, centrifuged, and resuspended in PBS. The up-
take of nrGO/DOX by A549 cells was measured by flow
cytometry (FCM, FACSCantoII, Becton Drive, NJ, USA),
and 10,000 events were recorded for each FCM analysis.
In addition, fluorescence microscope (IX73, Olympus,
Japan) with 488 nm excitation and 510–550 nm emis-
sion was used to image the uptake of nrGO/DOX by
A549 cells.
Cytotoxicity Assay
For cytotoxicity assay, ~5000 cells/well were plated in
96-well plate with 100 μL DMEM and cultured for 24 h.
After incubation with various concentrations of nrGO in
DMEM (10 % fetal calf serum) for another 24 h, the
relative cell viability was assessed by Cell Counting Kit-8
(CCK-8, Dojindo, Japan) assay with the auto microplate
reader as described previously [18].
To exclude the absorbance of nrGO at 450 nm,
every treatment group contained six wells, among
which the former three wells were treated by CCK-8
reagent whereas the later three wells by DMEM alone,
and the differences between the former three wells
and the later three wells were considered as the
absorption value of CCK-8 reagent. All experiments
were performed in triplicate.
For photothermal therapy, adherent cells were incu-
bated with various concentrations of nrGO for 3 h and
then irradiated by 808 nm laser for 5 min, and incubated
for an additional 21 h before CCK-8 assay.
Cytotoxicity of nrGO/DOX was also evaluated by
CCK-8 assay. The cells were allowed to adhere to a 96-
well plate overnight before adding nrGO/DOX. Cells
were treated with nrGO/DOX to take in for 4 h in
100 μL cell culture medium firstly. The cells with GSH
stimulation were treated by GSH at the concentration of
1.5 mM for 2 h, and the cells with 45 °C heating stimula-
tion were shaked in a shaking table at 45 °C for 1 h.
After 2 h of drug release treatment, the medium was
replaced by fresh medium and the cells were incubated
for a further 24 h for CCK-8 assay.
Statistics
Data were presented as mean ± SD from at least three
independent experiments. Statistical and graphic ana-
lyses were done using the software SPSS 19.0 (SPSS,
Chicago) and Origin 8.0 (OriginLab Corporation).
Results and Discussion
Synthesis and Characterization of nrGO
As shown in Scheme 1, to improve the stability of the
final product in physiological solution, we firstly oxi-
dated the aromatic structure of graphite oxide by nitro-
nium ion (NO2
+) at the aid of microwave irradiation for
3.75 min and then sonication for 1 h to achieve nano-
sized graphene oxide (nGO). Oxidation solution was
prepared by mixing 0.7 mL H2O, 4.2 mL concentrated
H2SO4, and 0.1 mL concentrated HNO3 orderly. Nitro-
nium oxidation was selected to reoxidate graphite oxide
in consideration of its simple process, easy elimination
of nitro, and much gentle oxidation level on graphite
oxide surface over the Hummer method [19, 20] as well
as the global oxidation involved the carbon atom within
both conjugated structure and oxygen-containing moi-
eties [21–25]. Figure 1a showed the relative NO2
+ con-
centration, being indicated by the Raman characteristic
peak counts at 1394 cm−1 from υ(NO) stretching [26], in
NO2
+ oxidation solution and water, respectively. Graphite
oxide was oxidated by nitronium oxidation solution to
achieve nGO with a high yield of 100 %. nGO-0 was fab-
ricated as control by directly sonicating graphite oxide
in an ice bath at 612 W for 1 h. The sizes of nGO-0 and
nGO were about 150 and 50 nm, respectively (Fig. 1b),
indicating that nitronium oxidation made the substance
more vulnerable to sonication.
The nGO was next reduced in pure glucose to restore
the conjugated structure and enhance the photothermal
effect (Scheme 1). Reaction was carried out by heating
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the nGO and glucose mixture with 1:22 of weight ratio
in autoclave at 135 °C for 30 min to obtain reduced
nGO (nrGO). The sizes of nrGO-0 and nrGO were about
70 and 40 nm, respectively (Fig. 1b), smaller than that of
nGO-0 and nGO, revealing that the chemical bond
between graphene sheets may be broken during the reduc-
tion process. The sheet thickness of nGO-0, nGO, nrGO-
0, and nrGO were approximately 1, 4, 1, and 2 nm,
respectively, indicating the bi-layer sheet of nrGO.
The UV-Vis spectra of nGO and nrGO suspensions
were exhibited in Fig. 2a. The absorption peaks of nGO
had a blue shift from 229 nm (nGO-0) to 224 nm due to
the destruction of the conjugated structure upon nitro-
nium ion oxidation. On the other hand, the increase in
visible light absorption of nGO indicated an exfoliation
of graphite oxide during microwave heating and nitro-
nium oxidation [27–29]. The absorption peaks of nrGO-
0 and nrGO shifted to 253 and 261 nm, respectively, and
their absorption at 808 nm wavelength increased more
than 40.2- and 52.8-folds, respectively, compared with that
of nGO-0 (Fig. 2a), demonstrating the restoration of con-
jugated structure and the better reduction of nrGO than
nrGO-0. The nrGO has more than a 10.2-fold increase in
absorption at 808 nm wavelength over the unreduced
nGO (Fig. 2a). Patel and co-workers have demonstrated
that when reacted with graphite, NO2
+ can attack the
defect-free graphene planes and etch the existing oxidized
sites [25]. It was also revealed that during nitronium oxi-
dation on graphite, multiple hydroxy and/or epoxy groups
were formed across the surface of the achieved graphene,
and subsequent oxidation resulted in more hydroxy and
epoxy groups which were preferentially formed away from
the carbon atoms already oxidized due to the electron-
donating capability of the resulting hydroxy and epoxy
groups [30–32]. We thus speculated that when attacked
by NO2
+, the original defects on graphite oxide were con-
sumed and the recovered graphite oxide was covered with
a set of elementary oxidation groups, such as hydroxy or
epoxy groups, making nGO more sensitive to the reduc-
tion conducted by aldehyde groups from glucose.
FTIR spectroscopy is an important tool for the struc-
tural characterization of GO-related materials [33]. For
nGO and nGO-0, the presence of intense bands at around
3400 cm−1(O-H), ~1720 cm−1 (C =O), ~1620 cm−1 (C =
C), ~1220 cm−1 (epoxy C-O), and ~1050 cm−1 (C-O)
(Fig. 2b) indicated the existence of oxygen-containing
Scheme 1 Schematic illustration of the preparation of reduced nano-graphene oxide (nrGO) through nitronium oxidation and glucose reduction
Fig. 1 a Raman spectra of NO2
+ in water and nitronium oxidation solution. b AFM images of nGO-0, nGO, nrGO-0, and nrGO
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moieties such as carbonyl, carboxylic, epoxy, and hy-
droxyl. In the FTIR spectrum of nGO, the reduced
absorption at approximately 1720 cm−1 due to the C =O
stretching and the replacing of the peaks at around 1220
and 1050 cm−1 (nGO-0) by a novel type of C-O bonds at
around 1110 cm−1 (Fig. 2b) also indicated the consump-
tion of original oxygen-containing groups on graphite
oxide surface upon nitronium oxidation. Since the
unbonded glucose can disperse in NaCl aqueous solution,
we added NaCl to nrGO solutions, and then centrifuged
and rinsed the precipitation ten times to obtain nrGO
without non-covalently bound glucose [34]. The resulting
nrGO was subjected to FTIR spectroscopy assay. Com-
pared with nGO, the enhanced peaks at ~1580 cm−1 of
nrGO (Fig. 2b) suggested a restoration of the carbon basal
plane. The greatly reduced peak at about 1230 and
3400 cm−1 of nrGO (Fig. 2b) indicated the removal of the
epoxy group and hydroxy. On the other hand, the pres-
ence of the peaks at ~2920 and ~2850 cm−1 correspond-
ing to the symmetric and antisymmetric stretching
vibrations of the CH2 group and the enhancement of the
peaks at ~1720 cm−1 attributed to the C =O stretching vi-
bration (Fig. 2b) demonstrated that a part of glucose was
covalently connected onto the surface of nrGO.
The Raman spectrum of graphene is characterized by
two main features: the G peak arising from the high-
frequency E2g phonon at the Brillouin zone center (usu-
ally observed at ~1575 cm−1) and the D peak arising
from the defects-activated breathing modes of six-atom
rings (~1350 cm−1). The G peak intensity (IG) is propor-
tional to the sample area, ∝ La
2 (La refers to the crystal
size), whereas ID is proportional to the overall length of
the edge, which scales as La, thus, the D/G intensity ra-
tio (ID/IG) varied inversely with La [35, 36]. As shown in
Fig. 2c, the ID/IG ratio of nGO is higher than that of
nGO-0, indicating the increase in both defects and edges
derived from nitronium oxidation. However, the ID/IG
ratio of nrGO-0 is lower than that of nrGO, indicating
that nitronium oxidation of graphite oxide made the
resulting nGO particles easier to be reduced and also
have fewer defects. However, the reductions of nGO
were incomplete as the D + D’ peaks at about 2920 cm−1
existed throughout the process, which may be beneficial
for the suspension of nrGO.
Biocompatibility and Photothermal Effect
In order to confirm the dispersibility of GO materials in
aqueous solution, we measured their mean diameter, poly-
dispersity index (Pdi) and zeta potential by dynamic light
scattering (DLS), and found that nGO and nrGO in water
had a stable diameter (Additional file 1: Figure S1A) and
Zeta potential (Additional file 1: Figure S1B) as well as Pdi
(Additional file 1: Figure S1C) for 2 months. The large
amount of glucose we used may act as not only a reduc-
tant but also stabilizer in consideration of the aggregation
tendency of reduced GO without dispersant [4, 5]. We
also evaluated the dispersion of these GO materials in fetal
bovine serum and DMEM containing 10 % of fetal bovine
serum, and found that all the samples except for nrGO-0
remained stable in fetal bovine serum for 1 month at 4 °C
(Fig. 3a upper), and that in DMEM, only nrGO kept stable
for 1 month (Fig. 3a lower), suggesting that it was the
nitronium oxidation of graphite oxide and subsequent glu-
cose reduction that endowed nrGO stability in DMEM.
Absorbance spectrum was employed to further verify the
good dispersibility of nrGO in DMEM (Fig. 3b). If a
homogeneous solution is formed, the absorbance should
be in a linear relationship with the concentration on the
basis of Beer’s law [37]. The insets of Fig. 3b showed that
there were good linear relationships (with R = 0.99978) be-
tween the absorbance at 350 nm and the concentrations
of nrGO from 20 to 100 μg/mL, demonstrating the great
dispersibility of nrGO in DMEM.
High NIR absorbance (Fig. 2a) allows nrGO to func-
tion as an effective photothermal reagent. As shown in
Fig. 4a, after 808 nm laser irradiation for 8 min, temper-
atures of water, 10 μg/mL of nGO-0, nGO, nrGO-0, and
nrGO solutions reached ~32.6, 34.2, 35.1, 47.1, and
Fig. 2 Spectroscopy characterization of nrGO. a UV-Vis spectra of nGO and nrGO. b FTIR spectra of nGO and nrGO. c Raman spectra of nGO and nrGO
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51.5 °C, respectively. Due to the prominent photother-
mal effect, nrGO was further investigated. As shown in
Fig. 4b, after 808 nm laser irradiation for 8 min, different
concentrations (2.5, 5, 30, 50, and 80 μg/mL) of nrGO
solution showed the temperatures of 40.3, 45.1, 66.8,
69.1, and 72.1 °C, respectively.
Characterization of Drug-Loaded nrGO
Doxorubicin (DOX), a broad-spectrum chemotherapeu-
tic agent, has been known to adsorb on graphene-based
materials via hydrophobic interaction and π-π stacking
[5, 38, 39]. The loading ratio of DOX was 317 % (w/w)
for nrGO and 318 % (w/w) for nrGO-0 by absorbance
measurements after separation of the unbound DOX
from nrGO/DOX solution (Fig. 5a). It was probably the
abundant hydrogen bonding sites from glucose deco-
rated on nrGO and nrGO-0 that endowed the reduced
the materials’ great loading capacity [38]. DOX loading
was also confirmed by monitoring the quenching of the
fluorescence of DOX (320 μg) upon the addition of in-
creasing weight (from 0 to 120 μg) of nrGO (Fig. 5b)
[10, 40]. As the weight of nrGO increased, the fluores-
cence intensity of DOX in solution weakened gradually
as a result of the non-radiative energy transfer between
excited DOX and nrGO which was sensitive to the dis-
tance between them [39]. Maximum quenching was
attained with 100 μg of nrGO (Fig. 5b), indicating the
saturated adsorption of DOX on nrGO being at 3.2-folds
of weight ratio.
Stimuli-Triggered Drug Release
Spatially and temporally controlled drug release trig-
gered by external stimulus is clinically significant for the
effective therapy in practical drug delivery applications
[10, 39, 41–44]. Here, we concentrated on stimuli-
responsive release of loaded drug molecules with heating,
GSH concentration, or acidic condition acting as stimulus.
GSH treatment for 6 h induced a dose-dependent recov-
ery of DOX fluorescence intensity of nrGO/DOX suspen-
sion (Fig. 5c, d), demonstrating that GSH treatment
triggered effective DOX release from the nrGO/DOX
complex. We also assessed the time-dependent DOX
Fig. 3 Dispersibility of nrGO. a Photographs of nGO and nrGO solutions in FBS and DMEM at the concentrations of 100 μg/mL after storage at 4 °C for
1 month. b Absorption spectra of nrGO dispersed in DMEM. Inset: correlation of absorbance at 350 nm against concentration
Fig. 4 Photothermal effect of nrGO. a Temperature curves versus time during irradiation with 808-nm laser (3 W/cm2) for Eppendorf tubes containing
water, nGO, and nrGO (10 μg/mL), respectively. b Temperature curves versus time during irradiation with 808-nm laser for Eppendorf tubes containing
various concentrations of nrGO
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release from the nrGO/DOX complex by acidic aqueous
solution (pH 5) and heating (50 °C) as well as GSH
(5 mM) stimulation, and found that the nrGO/DOX
complex was very stable in both aqueous solution and
DMEM (supplemented with 10 % fetal calf serum),
while acidic condition and heating as well as GSH
stimulus triggered a rapid DOX release from the
nrGO/DOX complex (Fig. 5d). Moreover, implementa-
tion of multiple stimuli stepwise to nrGO/DOX solu-
tion could induce a DOX release as high as 85 %
finally (Fig. 5e).
Acceleration of drug release upon heating is likely re-
lated to change of the binding energy between nrGO
and DOX [44]. Liu and co-workers reported that either
2-propanol or serum proteins induced drug release
through the disruption of noncovalent π–π stacking and
hydrophobic interactions between the drug and GO
sheets [4]. Similarly, GSH was deemed to weaken the as-
sembly of the aromatic interactions between nrGO and
the drug [39, 44]. At low pH, DOX becomes more
hydrophilic to dissociate from nrGO due to the proton-
ation of its NH2 group [45]. Since nrGO owns excellent
photothermal effect and the tumor is acid as well as the
intracellular conditions have millimolar concentration of
GSH, nrGO may thus be used as a controllable drug
loading and delivery platform for cancer therapy.
In Vitro Anticancer Effect of nrGO and nrGO/DOX
Considering the dispersibility of nrGO in DMEM (Fig. 3),
we selected nrGO for cell experiments. Since nrGO was
sterile, it was used for cells experiments directly. In order
to confirm the uptake of nrGO by tumor cells, we moni-
tored the delivery of nrGO/DOX in A549 cells just as
described previously [9, 10]. After being incubated with
nrGO/DOX (5 μg/ml of DOX equivalent) at different
times, the cells were rinsed with PBS to remove unincor-
porated chemicals, and FCM analysis was applied to assess
the cellular uptake of nrGO. Compared with the control
group, the cells cultured with nrGO/DOX for 1 h showed
strong fluorescence (Fig. 6a, b), indicating the effective up-
take of nrGO by cells. Besides, fluorescent microscopy
was also applied to confirm the attachment and engulf-
ment of nrGO/DOX by cells. A549 cells incubated with
nrGO/DOX for 1 h showed a strong fluorescence signal
in the cell nucleus (Fig. 6c), indicating that nrGO was
uptaked by cells after surface adhesion and the loaded
DOX entered the nucleus successfully.
Fig. 5 a Absorption spectra of nrGO (green) and nrGO-0 (gray) with (solid) or without (dash) DOX loading. Inset: comparison of drug loading capacity
of nrGO-0 and nrGO. b Fluorescence spectra of DOX mixed with different weights of nrGO. c Fluorescence spectra of nrGO/DOX after treatment with
different concentrations of GSH (0, 0.01, 0.05, 0.2, 0.5, 1, and 5 mM) for 6 h. d Plot of stimuli-induced DOX release from nrGO/DOX by acidic condition
(pH 5), GSH (5 mM), 50 °C water bath heating, and their combinations, respectively. e Sequential multi-stimuli-responsive DOX release profile from
nrGO/DOX complex under acidic condition (pH 5), GSH (5 mM), and 50 °C water bath heating
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CCK8 assay was used to assess the cytotoxicity and
photothermal toxicity of nrGO in HepG2, Huh7, and
A549 cells. Cells cultured with nrGO alone up to
100 μg/mL for 24 h did not exhibit a decrease in cell via-
bility whereas NIR irradiation for 5 min indeed induced
approximately 68.3, 54.8, and 76.2 % decrease in cell
viability for HepG2 (Fig. 6d), Huh7 (Fig. 6e), and
A549 (Fig. 6f ) cell lines incubated with 80 μg/mL
nrGO, demonstrating the excellent PTT efficacy of
nrGO to cancer cells.
Fig. 6 Cellular uptake and cytotoxicity of nrGO and nrGO/DOX. a Cellular uptake of nrGO/DOX in A549 cells by FCM assay. Cells were cultured
with nrGO/DOX for 1, 2, 6, and 12 h respectively before FCM analysis. b Statistical results of cellular uptake of nrGO/DOX in A549 cells from three
independent experiments. c Fluorescence images of living A549 cells cultured with nrGO/DOX. The adherent cells incubated with nrGO/DOX for
0, 1, 3, and 6 h were imaged by fluorescence microscope. d–f Dose-dependent cytotoxicity of nrGO with or without NIR irradiation on HepG2 (d),
Huh7 (e), and A549 (f) cells. g Cytotoxicity of nrGO/DOX with heating or GSH treatment in A549 cells. *P < 0.05 and **P < 0.01, compared with the
cells treated with nrGO/DOX alone
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Treatment with heating (45 °C) for 1 h or GSH
(1.5 mM) for 2 h significantly enhanced the cytotox-
icity of nrGO/DOX (Fig. 6g). It was reported that high
temperature enhanced the cellular uptake of the nano-
material possibly due to the increase in cell membrane
permeability [42, 46, 47]. Kim and co-workers demon-
strated that NIR irradiation effectively triggered DOX
release from a PEGylated GO/DOX complex in living
cells [44]. Therefore, we speculated that it was the ele-
vated cellular uptake of nrGO/DOX and the rapid
release of DOX from the nrGO/DOX complex by
heating or GSH treatment that contributed to the in-
creased cytotoxicity of nrGO/DOX.
Conclusions
In summary, we developed a facile and rapid green ap-
proach to fabricate nanosized, sterile nrGO for photo-
thermal therapy and drug delivery by using pure glucose
as reducing agent. Of the utmost importance, nitronium
oxidation of graphite oxide promotes the reduction de-
gree and biocompatibility of glucose-reduced nrGO. In
addition, the resulting nrGO has 317 % (w/w) of DOX
loading, and the DOX release from the nrGO/DOX
complex can be effectively enhanced by acid condition,
GSH concentration, and heating. Taken together, the
nrGO developed here may be a promising synergistic
nano-platform for photothermal therapy and control-
lable drug delivery, which can be further applied to the
nanomedicine field.
Additional File
Additional file 1: Figure S1. Change of nGO, nGO-0, nrGO and nrGO-0 in
mean diameter (Figure S1A), Zeta potential (Figure S1B) and Pdi (Figure S1C)
can be found in supplementary materials. (DOC 10464 kb)
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